Viromed Medical AG, a medical technology company specializing in cold plasma applications, announced on September 2, 2026, that Prof. Dr. Michael A. Rubhausen has joined its Medical Advisory Board with immediate effect. Rubhausen, a physicist and expert in spectroscopy, will lend his scientific expertise to the board, particularly in the fields of spectroscopy and materials research, to support the company's research and development efforts.
The appointment underscores Viromed's commitment to advancing cold plasma technology in medicine by integrating rigorous scientific analysis. Uwe Perbandt, CEO of Viromed Medical AG, commented, "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
Prof. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as the institute's Managing Director. He is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on modern spectroscopic methods, including Raman spectroscopy and ellipsometry, which he applies to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH. His interdisciplinary work has produced more than 180 publications with approximately 4,000 citations, appearing in prestigious journals like Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Another key area of his expertise is developing AI-supported analysis workflows for complex, high-dimensional datasets.
The addition of Rubhausen to the advisory board signals Viromed's intent to deepen its scientific foundation. The company, listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology through its wholly owned subsidiary Viromed Medical GmbH. Cold plasma, an ionized gas at near-ambient temperature, has shown promise in medical applications such as wound healing, disinfection, and cancer treatment. By engaging a physicist of Rubhausen's caliber, Viromed aims to better understand the interactions between plasma and biological materials, potentially leading to improved therapeutic products and new applications.
This strategic move highlights the growing importance of interdisciplinary collaboration in medical technology. As cold plasma gains traction in clinical settings, the ability to characterize its effects at a molecular level becomes crucial. Rubhausen's expertise in spectroscopy could enable Viromed to validate the efficacy of its products and tailor them to specific medical needs, thereby strengthening its competitive position in the DACH region and beyond. The company's broad customer base and ambitious growth plans may be further supported by the scientific credibility that such an appointment brings.
The news reflects a broader trend in the medical device industry, where companies increasingly invest in research and advisory expertise to navigate regulatory requirements and gain physician trust. While the immediate impact of Rubhausen's appointment may not be felt in financial terms, it represents a long-term investment in intellectual capital. For Viromed, which aims to realize the full potential of cold plasma technology, having a world-renowned scientist on board could prove instrumental in advancing both its research agenda and its market acceptance.
Prof. Rubhausen joins an advisory board that presumably includes other medical and scientific experts, though no additional details were provided in the announcement. His role will likely involve consulting on research strategies, evaluating scientific data, and guiding the company on future directions. With his extensive experience in materials science and spectroscopy, he is well-positioned to bridge the gap between fundamental physics and clinical application.
The appointment comes at a time when Viromed is seeking to expand its footprint in the medical plasma sector. According to industry reports, the global cold plasma market is projected to grow significantly in the coming years, driven by increasing applications in wound care, dentistry, and oncology. By aligning with top-tier scientists, Viromed is positioning itself to lead in this emerging field.
